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Abstract
Background: Selective allocation of patients into the compared groups of a randomised trial may cause allocation
bias, but the mechanisms behind the bias and its directionality are incompletely understood. We therefore analysed
the mechanisms and directionality of allocation bias in randomised clinical trials.
Methods: Two systematic reviews and a theoretical analysis. We conducted one systematic review of empirical
studies of motives/methods for deciphering patient allocation sequences; and another review of methods
publications commenting on allocation bias. We theoretically analysed the mechanisms of allocation bias and
hypothesised which main factors predicts its direction.
Results: Three empirical studies addressed motives/methods for deciphering allocation sequences. Main motives
included ensuring best care for patients and ensuring best outcome for the trial. Main methods included various
manipulations with randomisation envelopes. Out of 57 methods publications 11 (19 %) mentioned explicitly that
allocation bias can go in either direction. We hypothesised that the direction of allocation bias is mainly decided by
the interaction between the patient allocators’ motives and treatment preference.
Conclusion: Inadequate allocation concealment may exaggerate treatment effects in some trials while
underestimate effects in others. Our hypothesis provides a theoretical overview of the main factors responsible for
the direction of allocation bias.
Keywords: Allocation bias, Selection bias, Bias mechanisms, Systematic review, Randomised clinical trials, Direction
of bias
Background
In 1948 the British Medical Journal published the UK
Medical Research Council’s famous trial of streptomycin
treatment for pulmonary tuberculosis which is generally
regarded the first properly conducted randomised clin-
ical trial [1].
The planners of the streptomycin trial conceptualised
randomisation as a two-step process. The first step was
the generation of a random sequence: “… random sam-
pling numbers [were] drawn up for each sex at each
centre by Professor Bradford Hill” [1]. The second step
was the concealment of the random sequence from the
person responsible for inclusion of patients: “… the de-
tails of the series … were contained in a set of sealed
envelopes, each bearing on the outside only the name of
the hospital and a number.” In modern terminology
these two components of randomisation are usually
called “allocation sequence generation” and “allocation
sequence concealment”.
The main methodological rationale for randomisation
in a clinical trial is to protect against allocation bias, i.e.
to facilitate equal baseline distribution of prognostic fac-
tors between the compared groups. Allocation bias may
result from investigators knowing or predicting which
intervention the next eligible patient is supposed to get.
This knowledge may influence the information provided
to patients or the threshold for approaching a potentially
eligible patient, thereby selecting patients with a good
prognosis (i.e. anticipated good outcome and treatment
response) into one of the groups. Concealment of the al-
location sequence is often regarded the most important
aspect of the randomisation process.
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A trial is very vulnerable to allocation bias if no at-
tempts have been made to conceal the allocation se-
quence (for example the allocation list is openly
available). A more frequent scenario consists in inad-
equate concealment methods enabling deciphering of al-
location sequence (for example opening unsealed and
unnumbered convolutes) or intelligent guessing of allo-
cations when restricted randomisation is used (for ex-
ample block randomisation). In the latter case, trials that
use small, fixed and openly available block sizes may en-
able intelligent guessing of a considerable proportion of
patients (for example if block size is 2, the allocated
intervention can be deduced for half of the patients).
The theoretical considerations on allocation bias found
considerable support in a pivotal study of allocation con-
cealment (and other aspects of trial design), published in
1995 by Schulz and colleagues [2]. They reported that, on
average, trials with inadequate allocation concealment ex-
aggerated estimated treatment effects, i.e. odds ratios, by
41 %. This dramatic result promoted inadequate allocation
concealment as a leading cause of bias in clinical trials.
For example, up to 2008 allocation concealment was the
only risk of bias item incorporated in RevMan, the soft-
ware used for Cochrane Reviews [3]. However, the result
also encouraged a conception that allocation bias - to a
considerable extent - was unidirectional, typically exagger-
ating the experimental intervention.
Since 1995 several meta-epidemiological studies of al-
location concealment have reported inconsistent results.
An overview from 2012 combined seven such studies
and reported that trials with unclear or inadequate allo-
cation concealment exaggerated treatment effects by
only 7 % [4] and that the degree of bias, as well as the
degree of variation in estimated treatment effect from
trial to trial, was more pronounced in trials with subject-
ive outcomes. Another overview from 2016 found simi-
lar results [5]. Thus, the magnitude of allocation bias
appears considerably more uncertain than previously be-
lieved and related to background factors, such as type of
outcome.
Already in 1995 Schulz and colleagues emphasised
that allocation bias may “inconsistently bounce in both
directions …” [2]. However, this observation had much
less impact than their estimate of an average degree of
bias. If allocation bias indeed “bounce in both directions”
in more than a rare minority of trials it becomes a rele-
vant question which factors cause the directionality. We
have not identified any comprehensive analysis of this
question.
Thus, we decided to study the mechanisms and direc-
tionality of allocation bias. Our main objectives were: I)
to systematically review empirical studies of the motives
and methods of investigators allocating patients in a trial
with no, or inadequate, allocation concealment, or trials
where upcoming allocations are predictable, despite of
allocation concealment; II) to systematically review
methods publications commenting on mechanisms and
directionality of allocation bias; and III) to suggest a rea-
soned hypothesis for which main factors decide the dir-
ection of allocation bias.
Methods
This study consists of two systematic reviews and a the-
oretical analysis.
General terminology
By “allocation bias” we understand the bias caused by al-
locating patients with better prognosis to either the ex-
perimental or the control group. In the context of a
randomized trial the term “selection bias” is sometimes
used instead of allocation bias to indicate selection of
patients into treatment arms. We avoid the term “selec-
tion bias” as it has a different meaning in epidemiology
more broadly: selection of non-representative persons
into a study.
Concealment of allocation is sometimes confused with
blinding. We adhere to the standard terminology in
which “concealment of allocation” takes place before
and during patient allocation, whereas “blinding” (i.e.
keeping allocations hidden from trial participants, for
example patients and investigators) occurs after patient
allocation. We define adequate concealment of alloca-
tion as not only thwarting knowledge of future alloca-
tions, but also prediction due to intelligent guessing, for
example in trials with block randomisation.
We call the person in a randomised clinical trial re-
sponsible for recruitment and allocation of patients for
the “patient allocator”.
Systematic review of studies of the motives and
behaviours of patient allocators
We identified, summarised and analysed empirical stud-
ies of the motives and behaviours of investigators par-
ticipating in a trial with no allocation concealment or
deciphering the allocation sequence in a trial with
intended allocation concealment. We included all types
of empirical studies examining patient allocator motives
and behaviour in more than a single trial, for example
questionnaire surveys, interview studies, or personal ac-
counts. We excluded studies based only on a single trial
(but noted their results, and used these for a sensitivity
analysis).
We searched PubMed, the Cochrane Methodology
Register, and Google Scholar (see Additional file 1 for
detailed search strategy), and systematically read the list
of references in eligible studies and review articles. The
search was conducted on the 15th of March 2015. No
language restrictions were applied. One author (AP)
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screened all hits. If a text was judged potentially eligible,
the full text was read, and if clearly ineligible excluded.
All other publications were read by two authors (AP and
AH or DL).
Two authors (AP and either DL or AH) extracted data
independently. Disagreement was solved by discussion.
We extracted: type of study (i.e. questionnaire or inter-
view, vignette or actual trial), characteristics of the pa-
tient allocator, mechanism used to decipher allocation
sequence, and motives involved. We contacted the au-
thors of eligible studies if we thought that more detailed
outcome data could be obtained.
The design and results of each individual study were
noted. Risk of bias was assessed based on the individual
study design, i.e. in a questionnaire study mainly the re-
sponse rate and the risk of response bias and in a study
based on recollection of conversations with course par-
ticipants mainly the risk of response bias. The results of
the studies were summarised qualitatively.
As a sensitivity analysis we summarised studies of
allocator motives and behaviour when based only on
a single trial.
Systematic review of methods publications
We identified, summarised and analysed methods publi-
cations that commented on mechanisms or direction of
allocation bias. We included all types of publications, for
example textbooks on trial methodology and clinical
epidemiology and relevant sections from meta-
epidemiological studies, articles, editorials etc. We fo-
cused on identifying publications with a primary object-
ive to discuss allocation bias, but did also include
publications that commented on allocation bias without
this being the primary objective. We excluded publica-
tions that did not comment on either mechanisms or
directionality of allocation bias or that only expressed
peripheral remarks, i.e. remarks that were short (for ex-
ample 1–2 lines) or tangential to the subject (for ex-
ample allocation bias was mentioned but not reflected
upon).
We searched PubMed, the Cochrane Methodology
Register, Google Scholar, and selected textbooks using
the search strategy developed by Moustgaard and col-
leagues [5] and systematically read the references to eli-
gible studies and review articles (Additional file 1). The
data-base search was conducted on the 17th of March
2015. No language restrictions were applied.
One author (AP) screened all hits. If a text was judged
potentially eligible, the full text was read, and if clearly
ineligible excluded. All other publications were read by
two authors (AP and AH or DL). Disagreement was
solved by discussion.
Two authors (AP and DL) extracted data independ-
ently. Disagreement was solved by discussion.
For any included methods publication we extracted
the following data: type of publication (theoretical art-
icle, meta-epidemiological study, textbook, comment or
editorial), publication year, main subject (allocation con-
cealment/allocation bias or other), and the verbatim
quote of any comment on the mechanisms or direction
of allocation bias.
The individual comments were categorised according
to main content and tabulated based on general charac-
teristics, direction of allocation bias and mechanisms of
allocation bias.
Hypothesis for the main factors deciding the direction of
allocation bias
We developed a reasoned methodological hypothesis
(i.e. small theoretical model) for how motives and treat-
ment preferences in patient allocators transform into a
biased result in at trial. Based on methodological theory
(partly summarised in the previous parts of our paper)
as well as empirical studies [4, 5], we defined the main
motives and treatment preferences of the patient alloca-
tor in a clinical trial, and analysed how this could influ-
ence the allocation of patients and the direction of
allocation bias. In formulating a hypothesis we aimed for
one that that was coherent with the main empirical
studies, logically consistent, and intuitively plausible. We
also restricted our focus to the classical situation of a
two group parallel group randomised trial aiming to
study whether the experimental intervention was super-
ior to the control intervention.
By direction of bias we mean whether the outcome of
a trial exaggerates or underestimates the true treatment
effect. Thus, we use the term to determine the bias on a
trial level (not on the level of the individual allocator, or
the level of a meta-analysis).
Results
Systematic review of studies of the motives and
behaviours of patient allocators
Based on screening of 3419 publications, we read the full
text of 43 and excluded 40 (Additional file 1). Thus, we in-
cluded three studies of patient allocators’ behaviour and
motives when either participating in a trial without alloca-
tion concealment or deciphering the allocation sequence
in a trial intending to conceal the sequence [6–8].
Hewitt 2009 was a web-based survey of investigators
who were, or had been, involved in clinical trials [6]. A
total of 125 trial investigators were identified through
personal contacts and mailing lists of trial relevant orga-
nisations in the UK, 15 additional groups were identified
through the National Academic Mailing List service, and
an unknown number of contacts made as invited partici-
pants were asked to forward the email to anyone they
thought would be interested. A total of 268 persons
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responded to at least one question. The persons were
asked how many trials they knew of in which randomisa-
tion had been subverted (i.e. deciphered), and were
asked of an account of the separate incidences, including
the reasons for deciphering.
Some 30 survey responders provided details of deci-
phering (numbers not reported) or involvement in trials
with no concealment of allocation (numbers not re-
ported). Of the 30 responders, 14 referred to personal
experience, 11 referred to what others had told them,
two referred to secondary analyses (it is unclear what
“secondary analyses” means in this context) and one re-
ferred to the published literature (two responders did
not clarify what was the basis for their example of deci-
phering). The deciphering methods involved are sum-
marised in Table 1.
A “frequently reported reason” for deciphering the al-
location sequence was the intention to act in the interest
of the participants, i.e. allocating patients in greater need
to the treatment assumed to be best. A second “major
reason” was showing that a particular treatment worked,
i.e. facilitating a trial result that reflected the patient al-
locator’s preferred treatment. Other motives reported
were: pressure from patients, pressure from others in-
volved in the trial, practical/technical concerns, and lack
of knowledge. The survey did not report in detail which
motive was the most frequent. Contact to the authors
revealed that the study data were not available.
Schulz 1995 summarised conversations with methodo-
logical workshop participants (over 20 workshops with
20–25 persons each) conducted from 1988 to 1995 [7].
About half of the >400 participants recalled, or had wit-
nessed, a case of deciphering allocation sequence. There
were no explicit accounts of participants being part of
trials without any allocation concealment. The decipher-
ing methods involved are summarised in Table 1.
Schulz and colleagues did not ask about the motives
for deciphering, but they got some volunteered com-
ments. Frequently, workshop participants simply lacked
knowledge of the scientific ramifications while in one
case a surgeon wanted experience in a specific operating
procedure.
Brown [8] asked 25 clinicians and research nurses who
were actively recruiting patient into trials run by a clinical
trials unit whether they tried to predict patient allocations,
and if so, their motives and methods. Four of the 25
(16 %) stated that they tried to predict future allocations.
The motives reported by “a few” were that they hoped that
certain patients would be allocated to a specific treatment,
giving reasons such as “some would have a perceived
benefit from a particular treatment” or “patients would be
able to travel more easily”. The method used was by keep-
ing a log of all previous patient allocations (Table 1).
We considered the risk of bias as notable in all three
studies. Hewitt 2009 could not account the number of
potential participants in their survey due to their study
design so the response rate was not possible to assess.
Schulz 1995 involved recollections of informal conversa-
tions in public, so there is a considerable risk of re-
sponse bias. Furthermore, both studies included cases of
what others had witnessed (and in Hewitt 2009 one case
based on a published account). Brown 2005 was an ex-
plorative study with a small sample size, and it was un-
clear whether the answers were the result of a written
questionnaire or an oral interview.
As a sensitivity analysis we noted any reports of mo-
tives or methods of deciphering allocation sequence
based on a singular trial (which were excluded from the
main review). We identified five such trials. In one trial
the motives for deciphering was interpreted to be prac-
tical considerations (but this was not based on direct in-
terviews with the involved patient allocators). In the
remaining four trials the mechanisms mentioned either
involved manipulations with envelope randomisation or
in one trial that the coordinating investigator knew the
allocation schedule (Additional file 1).
Systematic review of methods publications
Based on screening of 1852 publications, we read the full
text of 130 publications of which 73 were excluded
(Additional file 1). Thus, we included 57 publications [2,
4, 6, 9–62], (Tables 2 and 3).
Table 1 Methods for deciphering a allocation sequence or
otherwise tampering with allocations in randomized trials,
based on a systematic review of three empirical studies on the
motives and behaviors of investigators recruiting patients to
clinical trials
Envelopes/drug containers
• Holding envelopes to light
• Opening envelopes before entering patient
• Entering two patients at the same time, and switching envelopes
• Judging weight difference between envelopes
• When using sequentially numbered drug containers, difference
of appearance
Central randomisation
• Several allocations given from central office, at the same time
• Clinician informed of next allocation, before deciding whether to enter
the patient
• Manipulation of lists (e.g. not writing patients on lists in the right
order)
Others
• Prediction of future assignments based on past assignments, when
using restricted randomisation (for example by keeping a log)
• Finding assignment sequence in chief investigators office
aSome studies employ no allocation concealment, in such cases no deciphering
takes place, but the resulting bias remains the same
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The directionality of allocation bias, was explicitly com-
mented on in 27 of 57 publications (53 %), however only 11
(19 %) [2, 14, 15, 29, 30, 42, 48, 51, 59, 61, 62] pointed out
that allocation bias can be bidirectional, the remaining 16
(28 %) [9, 13, 18–20, 26–28, 31, 34, 37, 38, 46, 53–55] only
mentioned that treatment effects could be exaggerated.
Eight of the 57 publications (14 %) [21, 22, 28, 30, 32,
42, 44, 61] proposed hypothetical scenarios in which
motives of patient allocator result in potential allocation
bias (Table 4).
Had we included only the 32 publications with a main
focus of addressing allocation bias, the results would
have been similar: 18 of 32 (56 %) publications commen-
ted on direction of bias, of which 6 (19 %) pointed out
that bias can be bidirectional.
Hypothesis for the main factors deciding the direction of
allocation bias
We developed a reasoned methodological hypothesis
(i.e. small theoretical model) for the direction of bias in
a parallel group superiority randomised trial. We as-
sumed that the main factors involved were patient allo-
cators’ treatment preference (either the experimental
intervention or the control intervention) and their
motive (either securing best patient care or boosting trial
result). By analysing how these factors could interact we
derived at a model, summarised in Fig. 1 and developed
in more detail below.
In a clinical trial a patient allocator will typically prefer
either the experimental or the control intervention. The
third possible situation involves a patient allocator who
is fully and truly neutral in all relevant clinical situations
(in which allocation bias is not a problem and conceal-
ment of allocation unnecessary); however, this is a very
unlikely situation (even patient allocators who consider
themselves neutral may not be so).
Which intervention is preferred (and the degree of
preference) differs from person to person and in a single
trial all patient allocators may not agree. Still, the initi-
ation of a randomised trial is typically driven by a con-
siderable degree of hope and positive expectations, so
seen as a group the patient allocators may typically pre-
fer the novel experimental intervention.
However, in special situations the patient allocators
may prefer the control intervention: when the effect of
the experimental intervention is regarded negligible or
inferior, for example in a trial of homeopathy vs. stand-
ard care for cancer, in an experimental non-surgical
intervention vs. a control routine surgical intervention,
or in a trial of the experimental oral format of a drug vs.
its intravenous control format [63].
Furthermore, the patient allocator typically has two
conflicting main motives: best patient care and best pos-
sible trial results. Which motive is the dominant one will
affect the direction of allocation bias. A patient allocator
who wants to (consciously or unconsciously) boost the
estimated effect of the preferred intervention will need
to channel patients with a good prognosis into the pre-
ferred intervention arm. On the contrary, a patient allo-
cator who wants the best care for patients will need to
channel patients with bad prognosis to the intervention
perceived as more effective as patients with a bad prog-
nosis are those in greatest need of the best treatment.
The motives may differ between patient allocators in a
given trial, but the net impact on a trial will reflect the
motives of the patient allocators as a group.
Table 2 Characteristics of methods publications addressing
allocation bias directionality and mechanisms
Publication characteristics n (%)
Total 57
Publication type
Theoretical article 33 (58 %)
Meta-epidemiological study 9 (16 %)
Textbook 12 (21 %)
Editorial 1 (2 %)
Comment 2 (3 %)
Publication topic
Allocation bias primary aim 32 (56 %)
Other 25 (44 %)
Year of Publication
1975–1984 1 (2 %)
1985–1994 3 (5 %)
1995–2004 18 (32 %)
2005–2014 35 (61 %)
Table 3 Major points in 57 methods publications addressing
allocation bias directionality and mechanisms
Direction of bias Na (%)
Studies explicitly commenting on direction of bias 27 of 57
(47 %)
Studies commenting only on exaggeration of
treatment effect
16 (28 %)
Studies commenting on possible bias in both
directions
11 (19 %)
Studies not explicitly commenting on direction of bias 30 of 57
(53)
Mechanisms of bias
Allocation concealment protects against allocation bias 53 of 57
(93 %)
Preferential allocation of patients may lead to bias. 32 of 57
(56 %)
Allocation bias is possible in trials with restricted
randomisationb, if upcoming assignments can be guessed.
11 of 57
(19 %)
aNumber; brestricted randomisation refers to the process of making restrictions
to the randomisation scheme (e.g. blocked randomisation)
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Table 4 Hypothetical scenarios described in 57 methods publications addressing allocation bias directionality and mechanisms
Favouring treatment: Favouring control: Direction unpredictable:
“An investigator for a pharmeceutical company,
very anxious to see the company’s latest
pharmaceutical product succeed, guesses the
randomization sequence and randomizes patients
he or she deems more likely to respond positively to
the new therapy when he believes the new therapy
to be next in the sequence” [21]a
“Or older patients might receive the traditional
therapy and youngsters the new one” [41]
“Because of the vested interest the sponsor may
have in the outcome of the trial (Hogel and Gaus,
1999), there may be a temptation to attempt to
bias trials towards more favorable outcomes.“ [27]
“…when clinicians know ahead of time which
treatment their next eligible and consenting patient
will receive, they may (consciously or unconsciously)
enter patients with lower risk and/or higher
responsiveness into the experimental treatment
group. As a result, the trial can become biased in
favor of experimental therapy from the start.” [29]
“The clinician might, for example, allocate the
patients with the worst prognosis to the, in his/her
opinion, ‘promising’ new therapy and the better
ones to the older treatment, no doubt with the
best possible intention in respect of his/her
patients” [41]
“On the other hand, in some unblinded trials, one
of the treatments may be systematically assigned
to the sickest patients. Randomization appears to
have been systematically slanted to make these
patients benefit from the test medication which
would appear to be more effective.” [31]
“A sympathetic nurse coordinator tries to assign a
favorite patient to the new therapy rather than
placebo” [21]
“If the referring health care provider knows the next
subject will be allocated to Slimmenowb, he/she
may be inclined to try to help a certain patient he/
she thinks may benefit more. Or perhaps knowing
the next subject is to be allocated to placebo, he/
she refers someone who really does not need to
lose much weight.” [61]
“They perhaps “know” the more effective treatment,
so they may want certain patients to benefit or
may want the results of a study to reveal what
they believe to be valid.” [20]
“For instance, if the referring clinician thinks that
treatment A is less effective than treatment B, and
he/she knows that the next subjects will be
allocated to treatment A and B, respectively, he/she
may be inclined to chose a patient with mild
symptoms for treatment A, and a patient with
more severe symptoms for treatment B.” [43]
aReferences indicate from which publication scenario is taken; bHypothetical experimental treatment
Fig. 1 The preference-motive interaction hypothesis for direction of allocation bias in randomised clinical trials. 1If dominant motive is best care for
patient, we expect patient allocator to channel patients with the worst prognosis into his/her preferred group, as these patients need the most
effective treatment the most; 2If the dominant motive is to boost the effect estimate of the preferred intervention, we expect patient allocator to
channel patients with better prognosis into preferred group, so the intervention will look more effective
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This hypothesis presupposes the ability of the patient
allocator to (better than chance) predict the prognosis of
patients, for example based on age, disease stage and co-
morbidity [64, 65]. Such prognostic ability may differ ac-
cording to type of disease or type of outcome. However,
our hypothesis presupposes that differences in prognos-
tic ability do not impact on the direction of allocation
bias, only on its degree. For simplicity we have not in-
corporated patient preferences into the hypothesis.
Discussion
Based on the three empirical studies, the main motives
for influencing patient allocation in a randomised trial
seem to be boosting the estimated effect of the experi-
mental intervention and to ensure best care for the
patient. Of 57 methods publications commenting on al-
location bias 11 (19 %) explicitly stated its dual direc-
tionality. We developed a hypothesis that the direction
of allocation bias is mainly influenced by the interaction
between the patient allocators’ treatment preference (ex-
perimental or control) and dominant motive (best pa-
tient care or boosting trial results).
To our knowledge this is the first review of studies of
the mechanisms and directionality of allocation bias.
Only three eligible studies were identified. An older
study from 1995 was based on recollections of what
>400 participants in methodology workshops had re-
vealed. Their experience may not be representative of
contemporary trials and recollections may not be fully
reliable. A study from 2005 was a small study with only
25 participants. The newer study from 2009 was a web-
based survey of >268 participants. Only 30 responders
provided details of mechanisms and motives of decipher-
ing. Results from the three studies were consistent, but
clearly there is a high risk of both non-response bias
[66] and response bias [67] in such surveys of problem-
atic behaviour. We stress that our results reflect re-
ported conduct, which may not accurately reflect actual
conduct. There remains a fundamental uncertainty of
how often deciphering takes place, but little doubt that
it does take place, and it is likely that the motives for
deciphering allocation sequence differ considerably.
We are fairly confident that we identified most
methods publications aiming to discuss allocation bias.
However, minor comments in publications with other
primary intentions are challenging to identify and some
may have been overlooked. Also, the distinction between
minor comments (which are included) and peripheral
statements (which are excluded) is to some degree sub-
jective. Our results, however, were similar when exclud-
ing minor comments. Our hypothesis proposes a simple
mechanism for the dual directionality of allocation bias,
and was informed by empirical studies and methods
publications.
Considering the importance of allocation bias for trial
methodology it is remarkable that only three studies of
the mechanism and motives for allocation deciphering
seem to have been conducted. We identified five trials
reporting on potential deciphering in individual trials, all
had been identified and commented on before [29]. We
excluded such studies because of a high risk of publica-
tion bias. Still, the results of these trials were consistent
with that of the studies we included. This lack of re-
search into mechanisms and motives may partly reflect a
prevalent conception among researchers that empirical
studies of allocation bias are more important than stud-
ies of its mechanisms, or that the challenges involved in
asking trial investigators about potentially problematic
procedures might be too difficult to overcome.
The problem of the directionality of allocation bias is
part of a broader discussion of the direction of bias in
general. Kunz and colleagues compared randomised and
non-randomised studies and reported a heterogeneous
pattern of results without one design type, on average,
finding higher estimates of treatment effects. They
coined the phrase “unpredictability paradox” to describe
this phenomenon [14]. Though it is unclear to which de-
gree such studies compare “like with like”, the under-
lying predicament could well be the directionality of
bias. A similar problem could impact on the empirical
challenges of assessing other types of bias in randomised
trials, for example bias due to attrition, blinding and out-
come selection [5, 68].
A main theoretical discussion following Schulz and col-
leagues’ 1995 study [2] was whether the association be-
tween inadequate allocation concealment and exaggerated
treatment effects was causal or whether it (to some extent)
was a marker of other biases. The finding in meta-
epidemiological studies that bias was more pronounced in
trials with subjective outcomes was unexpected [4, 5].
One possibility is that allocation concealment and blind-
ing may have been incompletely separated in the meta-
epidemiological studies, for example due to unclear
reporting in trial reports. Another possibility is that clini-
cians are less able to predict prognosis in trials that assess
mortality (for example in large preventive cardiovascular
trials) than in other trials. Both interpretations fit with the
mechanisms of our proposed hypothesis.
Which patient allocator motive is the dominant one in
a trial differs from patient allocator to patient allocator.
It is interesting to reflect on possible factors associated
with such motives. Boosting the estimated treatment ef-
fect may be a dominant motive in trials where the pa-
tient allocator is deeply involved in the planning, design
and execution of the trial (or if an allegiance has been
established between the investigators and the sponsors
of the trial) and in trials including patients with a revers-
ible condition, for example acute pain. Similarly, best
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patient care may be a more dominant motive in trials in
which the patient allocator’s only role is including pa-
tients or in trials including patients with a potentially ir-
reversible condition (high risk of death or of permanent
disability).
Our hypothesis thus predicts that allocation bias in
many trials initiated and run by clinicians will exaggerate
the estimated treatment effect when the patient allocators
prefer the experimental intervention. This is probably a
fairly typical situation, also because inadequate allocation
concealment tends to be more frequent in such trials.
Many contemporary trials initiated and run by other than
the investigator (for example a foundation, research coun-
cil or industry) will be large multi-centre trials. Such trials
are often conducted with concealment of allocation, but
our hypothesis predicts that if clinicians consider the ex-
perimental intervention superior, any allocation bias may
tend to underestimate the experimental treatment effect.
However, the direction of bias may partly depend on the
ability of the initiators of the trial, for example a drug
company, to create a bond of loyalty in the investigators
who allocate patients. Thus, though we hypothesise the
main factors behind the directionality of allocation bias, it
remains challenging to predict the direction of allocation
bias in an individual trial without knowledge of the prefer-
ences and motives of the involved clinicians.
Our hypothesis was not designed to be tested empiric-
ally, and there are considerable difficulties in studying
the relation between patient allocators’ motives, treat-
ment preferences and actual behaviour in a real trial,
partly because of a high risk that the initiation of the
study would change the behaviour it is set up to assess.
A practically feasible but more indirect study approach
would be to ask actual or possible patient allocators
about treatment preferences, motives and behaviour
based on constructed theoretical scenarios.
Allocation bias is driven by the lack of neutrality of
the clinicians including patients into the trial. This con-
trasts the ethical prerequisite for a clinical trial: equi-
poise, i.e. that there is a considerable degree of
uncertainty with respect to which intervention is best.
From an academic perspective, equipoise is an attractive
ideal, but in practice there will be a considerable differ-
ence between the position of individual clinicians and
the clinical community at large [69], and also a large
grey zone in which some uncertainty coexists with a
considerable degree of expectation that an experimental
intervention is effective.
Lack of insight in the scientific importance of alloca-
tion bias is probably an important background factor for
allocation bias but ignorance is insufficient in itself for
inducing allocation bias. If all persons involved in the
unconcealed allocation process in a trial were ignorant
about the scientific importance of avoiding allocation
bias and had no preferences errors in the allocation
process would occur by chance, which would increase
random variation but not cause bias.
Our model presupposes a parallel group randomized
trial. In cross-over trials allocation bias will have less in-
fluence on treatment estimate effects as patients will re-
ceive both experimental and control intervention during
the trial. Our model also presupposes a superiority ap-
proach in which the purpose of the trial is to test
whether the experimental intervention is superior to the
control intervention. Some trials are designed as non-
inferiority trials. Which intervention is preferred by the
person responsible for patient allocation is less clear in
such trials. In some situations the experimental inter-
vention is preferred because it may be more practical to
administer but in other trials it may be considered infer-
ior to the established control intervention [63].
Our study provides a framework for the interpretation
of risk of bias in clinical trials with inadequate allocation
concealment (for example when included in meta-
analyses) and for the interpretation of results of meta-
epidemiological studies. Our study also documents a
paucity of empirical studies on the treatment preferences
and motives of investigators allocating patients in clin-
ical trials. Considering the importance of allocation bias
to clinical trials methodology, we suggest that further
studies of the mechanisms of bias are warranted. Await-
ing results from such studies, our hypothesis can be
used as a tentative conceptual tool when reflecting on
the direction of allocation bias in a given trial.
Conclusion
Trial investigators who allocate patients in a randomised
trial may have different treatment preferences and con-
flicting motives for influencing patient allocation. Inad-
equate allocation concealment may exaggerate treatment
effects in some trials while underestimate effects in others.
This important dual directionality of allocation bias is not
a prominent feature of trial methodology publications. It
is challenging to predict the direction of allocation bias in
an individual trial without knowledge of the preferences
and motives of the involved clinicians, but our hypothesis
provides a theoretical overview of the main factors re-
sponsible for the direction of allocation bias.
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